Login to Your Account

Genzyme Hits EPS Estimates, Reports Delay In Renagel Trial

By Brady Huggett

Thursday, April 17, 2003
Genzyme General's first-quarter revenue blossomed nicely and the company hit its earnings-per-share estimates, but the revelation of a data delay from a Renagel trial dropped the company's stock Wednesday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription